Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy - Preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline

Medical Hypotheses

Volumn 50, Issue 5, 1998, Pages 435-449

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ANTIOXIDANT; ARGININE; CARNITINE; CHROMIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESSENTIAL FATTY ACID; ESTROGEN DERIVATIVE; FISH OIL; GAMMA LINOLENIC ACID; GINKGOLIDE DERIVATIVE; NITRIC OXIDE; PENTOXIFYLLINE; PROBUCOL;

ARTICLE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; HUMAN; ISCHEMIA; LEUKOCYTE ACTIVATION; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0031747534     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90217-1     Document Type: Article

References (267)

1. Durante W, Sen A K, Sunahara F A. Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol 1988; 94: 463-468.
2. Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharrnacol 1989; 97: 614-618.
3. Tesfamariam B, Brown M L, Cohen R A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991; 87: 1643-1648.
4. McVeigh G E, Brennan G M, Johnston G D et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
5. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992; 90: 2548-2554.
6. Pieper G M, Gross G J. Endothelial dysfunction in diabetes. In: Rubanyi G M, ed. Cardiovascular Significance of Endothelium-Derived Vasoactive Factors. Mount Kisco, NY: Futura, 1991: 223-249.
7. Karasu C, Allan V M. The role of endothelial cells on the alterations in vascular reactivity induced by insulin-dependent diabetes mellitus: effects of insulin treatment. Gen Pharrnacol 1993; 24: 743-755.
8. Poston L, Taylor P D. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci 1995; 88: 245-255.
9. Petrie J R, Ueda S, Webb D J et al. Endothelial nitric oxide production and insulin sensitivity. Circulation 1996; 93: 1331-1333.
10. Shore A C, Morris S J, Tooke J E. Is endothelial cell function impaired in the pre-diabetic state? Diabetes 1996; 45(Suppl. 2): 264A.
11. Baron A D. The coupling of glucose metabolism and perfusion in human skeletal muscle: the potential role of endothelium-derived nitric oxide. Diabetes 1996; 45(Suppl. 1): S105-S109.
12. Moreau P, Yamaguchi N, de Champlain J. Increased activity in the nitric oxide pathway during chronic euglycemic hyperinsulinemia in the rat. J Hypertens 1993; 11(Suppl. 5): S270-S271.
13. Steinberg H O, Brechtel G, Johnson A et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179.
14. Scherrer U, Randin D, Vollenweider P et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515.
15. Baron A D. Hemodynamic actions of insulin. Am J Physiol 1994; 267: E187-E202.
16. Young M E, Radda G K, Leighton B. A role for nitric oxide in stimulation of glucose metabolism in skeletal muscle. Diabetes 1996; 45(Suppl. 2): 94A.
17. Clausen T, Hansen O. Active Na-K transport and the rate of ouabain binding: the effect of insulin and other stimuli on skeletal muscle and adipocytes. J Physiol 1977; 270: 415-430.
18. Lückhoff A, Busse R. Calcium influx into endothelial cells and formation of endothelium-derived relaxing factor is controlled by the membrane potential. Pflügers Arch 1990; 416: 305-311.
19. Himmel H M, Whorton A R, Strauss H C. Intracellular calcium, currents, and stimulus-response coupling in endothelial cells. Hypertension 1993; 21: 112-127.
20. +-pump inhibitors and membrane depolarizing agents on acetylcholine-induced endothelium-dependent relaxation and cyclic GMP accumulation in rat aorta. Eur J Pharmacol 1985; 110: 203-209.
21. Busse R, Mülsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 1990; 265: 133-136.
22. Lückhoff A, Pohl U, Mülsch A, Busse R. Differential role of extra- and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. Br J Pharmacol 1988; 95: 189-196.
23. Wu G, Majumdar S, Zhang J et al. Insulin stimulates glycolysis and pentose cycle activity in bovine microvascular endothelial cells. Comp Biochem Physiol 1994; 108C: 179-185.
24. Knowles R G, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298: 249-258.
25. Inoguchi T, Battan R, Handler E et al. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-11063.
26. Inoguchi T, Xia P, Kunisaki M et al. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol 1994; 267: E369-E379.
27. Ishii H, Jirousek M R, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272: 728-731.
28. Weinheimer G, Wagner B, Osswald H. Interference of phorbolesters with endothelium-dependent vascular smooth muscle relaxation. Eur J Pharmacol 1986; 130: 319-322.
29. Lewis M J, Henderson A H. A phorbol ester inhibits the release of endothelium-derived relaxing factor. Eur J Pharmacol 1987; 137: 167-171.
30. Rubanyi G M, Desiderio D, Luisi A et al. Phorbol dibutyrate inhibits release and action of endothelium-deriving relaxing factor(s) in canine blood vessels. J Pharm Exp Ther 1989; 249: 858-863.
31. Guillon G, Mouillac B, Savage A L. Modulation of hormone-sensitive phospholipase C. Cell Signall 1992; 4: 11-23.
32. Matsubara T, Ziff M. Superoxide anion release by human endothelial cells: synergism between a phorbol ester and a calcium ionophore. J Cell Physiol 1986; 127: 207-210.
33. Murphy H S, Shayman J A, Till G O et al. Superoxide responses of endothelial cells to C5a and TNF-α divergent signal transduction pathways. Am J Physiol 1992; 263: L51-L59.
34. Bohlen H G, Lash J M. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 1993; 265: H219-H225.
35. Heller R, Bussolino F, Ghigo D et al. Protein kinase C and cyclic AMP modulate thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochim Biophys Acta 1991; 1093: 55-64.
36. Kukreja R C, Kontos H A, Hess M L, Ellis E F. PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res 1986; 59: 612-619.
37. Mügge A, Elwell J H, Peterson T E, Harrison D G. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol 1991; 260: C219-C225.
38. Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 1991; 261: H1086-H1094.
39. Diederich D, Skopec J, Diederich A, Dai F-X. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 1994; 266: H1153-H1161.
40. Beckman J S, Beckman T W, Chen J et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-1624.
41. Ting H H, Timimi F K, Boles K S et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
42. Hawthorne G C, Bartlett K, Hetherington C S, Alberti K G M M. The effect of high glucose on polyol pathway activity and myoinositol metabolism in cultured human endothelial cells. Diabetologia 1989; 32: 163-166.
43. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994; 94: 853-859.
44. Tomlinson D R. Aldose reductase inhibitors and the complications of diabetes mellitus. Diabetic Med 1993; 10: 214-230.
45. Greene D A, Sima A A F, Stevens M J et al. Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diab/Metab Rev 1993; 9: 189-217.
46. Hunt J V, Dean R T, Wolff S P. Hydroxyl radical production and autoxidative glycosylation: glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 1988; 256: 205-212.
47. Sakurai T, Tsuchiya S. Superoxide production from non-enzymatically glycated protein. FEBS Lett 1988; 236: 406-410.
48. Wolff S P, Jiang Z Y, Hunt J V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radical Biol Med 1991; 10: 339-352.
49. Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991; 87: 432-438.
50. Tesfamariam B, Cohen R A. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263: H321-H326.
51. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; ii: 997-1000.
52. Pohl U, Wagner K, De Wit C. Endothelium-derived nitric oxide in the control of tissue perfusion and oxygen supply: physiological and pathophysiological implications. Eur Heart J 1993; 14(Suppl. 1): 93-98.
53. Stamler J S, Loh E, Roddy M-A et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89: 2035-2040.
54. Radomski M W, Palmer R M J, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-187.
55. Arndt H, Russell J B, Kurose I et al. Mediators of leukocyte adhesion in rat mesenteric venules elicited by inhibition of nitric oxide synthesis. Gastroenterology 1993; 105: 675-680.
56. Kubes P, Suzuki M, Granger D N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655.
57. Bath P M W, Hassall D G, Gladwin A-M et al. Nitric oxide and prostatcyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb 1991; 11: 254-260.
58. Heller R, Bussolino F, Ghigo D et al. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem Pharm 1992; 44: 223-229.
59. + ATPase activity in rabbit aorta by hyperglycemia. J Clin Invest 1992; 90: 727-732.
60. Lee T-S, MacGregor L C, Fluharty S J, King G L. Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 1989; 83: 90-94.
61. Hattori Y, Kasai K, Banba N et al. Effect of a phorbol ester on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Endocrinol Jpn 1992; 39: 341-345.
62. Emori T, Hirata Y, Ohta K et al. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991; 18: 165-170.
63. Kohno M, Yokokawa K, Horio T et al. Release mechanism of endothelin-1 and big endothelin-1 after stimulation with thrombin in cultured porcine endothelial cells. J Vasc Res 1992; 29: 56-63.
64. Yamauchi T, Ohnaka K, Takayanagi R et al. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990; 267: 16-18.
65. Takahashi K, Ghatei M A, Lam H-C et al. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990; 33: 306-310.
66. Simpson L O. Altered blood rheology in the pathogenesis of diabetic and other neuropathies. Muscle Nerve 1988; 11: 725-744.
67. Johnson M, Harrison H E, Raftery A T, Elder J B. Vascular prostacyclin may be reduced in diabetes in man. Lancet 1979; i: 325-326.
68. Silberbauer K, Schernthaner G, Sinzinger H et al. Decreased vascular prostacyclin in juvenile-onset diabetes. N Engl J Med 1979; 300: 366-367.
69. 2) synthesis. Artery 1980; 8: 30-36.
70. Harrison H E, Reece A H, Johnson M. Effect of insulin treatment on prostacyclin in experimental diabetes. Diabetologia 1980; 18: 65-68.
71. Gerrard J M, Stuart M J, Rao G H R et al. Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med 1980; 95: 950-958.
72. Halushka P V, Mayfield R, Colwell J A. Insulin and arachidonic acid metabolism in diabetes mellitus. Metabolism 1985; 34(Suppl. 1): 32-36.
73. Kazama Y-I, Kanemaru Y, Noguchi T, Onaya T. Reevaluation of circulating prostacyclin and thromboxane in diabetes. Prost Leuk Med 1987; 26: 115-122.
74. 2 balance in diabetic rat. Influence of dietary vitamin E. Diabetes 1982; 31: 947-951.
75. Gilbert V A, Zebrowski E J, Can A C. Differential effects of megavitamin E on prostacyclin and thromboxane synthesis in streptozotocin-induced diabetic rats. Horm Metab Res 1983; 15: 320-325.
76. Mercuri O, Peluffo R O, Brenner R R. Depression of microsomal desaturation of linoleic to gamma-linolenic acid in the alloxan-diabetic rat. Biochim Biophys Acta 1966; 116: 409-411.
77. Cunnane S C, Manku M S, Horrobin D R. Abnormal essential fatty acid composition of tissue lipids in genetically diabetic mice is partially corrected by dietary linoleic and gamma-linolenic acids. Br J Nutr 1985; 53: 449-458.
78. Tilvis R S, Helve E, Miettinen T A. Improvement of diabetic control by continuous subcutaneous insulin infusion therapy changes fatty acid composition of serum lipids and erythrocytes in type 1 (insulin-dependent) diabetes. Diabetologia 1986; 29: 690-694.
79. Jones D B, Carter R D, Haitas B, Mann J I. Low phospholipid arachidonic acid values in diabetic platelets. Br Med J 1983; 286: 173-175.
80. 1α concentrations, and diabetic retinopathy. Br Med J 1981; 282: 1259-1262.
81. Ylikorkala O, Kaila J, Viinikka L. Prostacyclin and thromboxane in diabetes. Br Med J 1981; 283: 1148-1150.
82. Hayashi M, Imai Y, Oh-ishi S. Phorbol ester stimulates PAF synthesis via the activation of protein kinase C in rat leukocytes. Lipids 1991; 26: 1054-1059.
83. Nieto M L, Velasco S, Crespo M S. Modulation of acetyl-coA: 1-alkyl-2-lyso-sn-glycero-3-phosphocholine (lyso-PAF) acetyltransferase in human polymorphonuclears. J Biol Chem 1988; 263: 4607-4611.
84. Whatley R E, Nelson P, Zimmerman G A et al. The regulation of platelet-activating factor production in endothelial cells. J Biol Chem 1989; 264: 6325-6333.
85. Kurose I, Kubes P, Wolf R et al. Inhibition of nitric oxide production: mechanisms of vascular albumin leakage. Circ Res 1993; 73: 164-171.
86. Hirata M, Kohse K P, Chang C-H et al. Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. J Biol Chem 1990; 265: 1268-1273.
87. Zimmerman G A, McIntyre T M, Prescott S M. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest 1985; 76: 2235-2246.
88. Zimmerman G A, Prescott S M, McIntyre T M. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today 1992; 13: 93-99.
89. Granger D N, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994; 55: 662-675.
90. Lane T A, Lamkin G E, Wancewicz E. Modulation of endothelial cell expression of intercellular adhesion molecule 1 by protein kinase C activation. Biochem Biophys Res Commun 1989; 161: 945-952.
91. Wertheimer S J, Myers C L, Wallace R W, Parks T P. Intercellular adhesion molecule-1 gene expression in human endothelial cells. J Biol Chem 1992; 267: 12030-12035.
92. Kubes P, Grisham M B, Barrowman J A et al. Leukocyte-induced vascular protein leakage in cat mesentery. Am J Physiol 1991; 261: H1872-H1879.
93. 4 mediates shear rate dependent leukocyte adhesion in mesenteric venules. Circ Res 1992; 71: 906-911.
94. Bednar M, Smith B, Pinto A, Mullane K M. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Circ Res 1985; 57: 131-141.
95. Mullane K M, Salmon J A, Kraemer R. Leukocyte-derived metabolites of arachidonic acid in ischemia-induced myocardial injury. Fed Proc 1987; 46: 2422-2433.
96. Gaboury J P, Anderson D C, Kubes P. Molecular mechanisms involved in superoxide-induced leukocyte-endothelial cell interactions in vivo. Am J Physiol 1994; 266: H637-H642.
97. Worthen G S, Schwab B III, Elson E L, Downey G P. Mechanics of stimulated neutrophils: cell stiffening induces retention in capillaries. Science 1989; 245: 183-186.
98. Schmid-Schönbein G W. Capillary plugging by granulocytes and the no-reflow phenomenon in the microcirculation. Fed Proc 1987; 46: 2397-2401.
99. Ernst E, Hammerschmidt D E, Bagge U et al. Leukocytes and the risk of ischemic diseases. J Am Med Assoc 1987; 257: 2318-2324.
100. Alderman M J, Ridge A, Morley A A et al. Effect of total leucocyte count on whole blood filterability in patients with peripheral vascular disease. J Clin Pathol 1981; 34: 163-166.
101. Matrai A, Ernst E. Pentoxifylline improves white cell rheology in claudicants. Clin Hemorheol 1985; 5: 483-491.
102. Barnes A J, Locke P, Scudder P R et al. Is hyperviscosity a treatable component of diabetic micro-circulatory disease? Lancet 1977; ii: 789-791.
103. Fuller J H, Keen H, Jarrett R J et al. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-966.
104. MacRury S M, Lowe G D O. Blood rheology in diabetes mellitus. Diabetes Med 1990; 7: 285-291.
105. Newrick P G, Wilson A J, Jakubowski J et al. Sural nerve oxygen tension in diabetes. Br Med J 1986; 293: 1053-1054.
106. Tuck R R, Schmelzer J D, Low P A. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984; 107: 935-950.
107. Cameron N E, Cotter M A, Low P A. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991; 261: E1-E8.
108. Low P A, Tuck R R, Dyck P J et al. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci USA 1984; 81: 6894-6898.
109. 1 analogue TRC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Diabetes 1989; 38: 832-838.
110. Low P A, Schmelzer J D, Ward K K, Yao J K. Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. Am J Physiol 1986; 250: E94-E99.
111. Stevens M J, Feldman E L, Greene D A. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabetic Med 1995; 12: 566-579.
112. Aiello L P, Avery R L, Arrigg P G et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
113. Aiello L P, Northrup J M, Keyt B A et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538-1544.
114. Porta M. Endothelium: the main actor in the remodelling of the retinal microvasculature in diabetes. Diabetologia 1996; 39: 739-744.
115. Kunisaki M, Bursell S-E, Clermont A C et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 1995; 269: E239-E246.
116. Schröder S, Palinski W, Schmid-Schönbein G W. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81-100.
117. Müller H K, Kellerer M, Ermel B et al. Prevention by protein kinase C inhibitors of glucose-induced insulin-receptor tyrosine kinase resistance in rat fat cells. Diabetes 1991; 40: 1440-1448.
118. Kunisaki M, Bursell S-E, Umeda F et al. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 1994; 43: 1372-1377.
119. Lee I-K, Koya D, Ishii H, King G L. Vitamin E (vit E) prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity. Diabetes 1996; 45(Suppl.2): 64A.
120. Koya D, Lee I-K, Ishii H, Bursell S-E. Vitamin E normalized glomerular hyperfiltration and protein kinase C activation by increasing diacylglycerol kinase in diabetic rats. Diabetes 1996; 45(Suppl. 2): 205A.
121. Tran K, Proulx P R, Chan A C. Vitamin E suppresses diacylglycerol (DAG) level in thrombin-stimulated endothelial cells through an increase of DAG kinase activity. Biochim Biophys Acta 1994; 1212: 193-202.
122. Trachtman H, Futterweit S, Beinkowski R S. Taurine prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells. Biochem Biophys Res Commun 1993; 191: 759-765.
123. Trachtman H, Futterweit S, Prenner J, Hanon S. Antioxidants reverse the antiproliferative effect of high glucose and advanced glycosylation end products in cultured rat mesangial cells. Biochem Biophys Res Commun 1994; 19: 346-352.
124. McCarty M F. A central role for protein kinase C overactivity in diabetic glomerulosclerosis - implications for prevention with antioxidants, fish oil, and ACE inhibitors. Med Hypotheses 1998; 50: 155-165.
125. Marsh J B, Topping D L, Nestel P J. Comparative effects of dietary fish oil and carbohydrate on plasma lipids and hepatic activities of phosphatidate phosphohydrolase, diacylglycerol acyltransferase and neutral lipase activities in the rat. Biochim Biophys Acta 1987; 922: 239-243.
126. Wong S-H, Marsh J B. Inhibition of apolipoprotein secretion and phosphatidate phosphohydrolase activity by eicosapentaenoic and docosahexaenoic acids in the perfused rat liver. Metabolism 1988; 37: 1177-1181.
127. Surette M E, Whelan J, Broughton K S, Kinsella J E. Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty acids. Biochim Biophys Acta 1992; 1126: 199-205.
128. McVeigh G E, Brennan G M, Johnston G D et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 33-38.
129. Shimokawa H, Lam J Y T, Chesebro J H et al. Effects of dietary supplementation with cod-liver oil on endothelium-dependent responses in porcine coronary arteries. Circulation 1987; 76: 898-905.
130. Boulanger C, Schini V B, Hendrickson H, Vanhoutte P M. Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Br J Pharmacol 1990; 99: 176-180.
131. Lee T H, Hoover R L, Williams J D et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985; 312: 1217-1224.
132. Kremer J M, Robinson D R. Studies of dietary supplementation with ω3 fatty acids in patients with rheumatoid arthritis. In: Simopoulos A P, Kifer R R, Martin R E, Barlow S M, eds. Health Effects of ω3 Polyunsaturated Fatty Acids in Seafoods. World Rev Nutr Diet, Vol. 66. Basel: Karger, 1991: 367-382.
133. Arm J P, Horton C E, Spur B W et al. The effects of dietary supplementation with fish oil lipids on the airways response to inhaled allergen in bronchial asthma. Am Rev Respir Dis 1989; 139: 1395-1400.
134. Sperling R I. Effects of dietary fish oil on leukocyte leukotriene and PAF generation and on neutrophil chemotaxis. In: Health Effects of ω3 Polyunsaturated Fatty Acids in Seafoods. World Rev Nutr Diet, Vol. 66. Basel: Karger, 1991: 391-400.
135. 5 in complement receptor enhancement, lysozyme release and chemotaxis of human neutrophils. Clin Sci 1988; 74: 467-475.
136. Radack K, Deck C, Huster G. Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized, double-blind controlled study. Ann Intern Med 1989; 111: 57-758.
137. Høstmark A T, Bjerkedal T, Kierulf P et al. Fish oil and plasma fibrinogen. Br Med J 1988; 297: 180-181.
138. Saynor R, Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids 1992; 27: 533-538.
139. Sperling R I, Robin J-L, Kylander K A et al. The effects of n-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytes. J Immunol 1987; 139: 4186-4191.
140. Lehr H-A, Hübner C, Nolte D et al. Dietary fish oil blocks the microcirculatory manifestations of ischemia-reperfusion injury in striated muscle in hamsters. Proc Natl Acad Sci USA 1991; 88: 6726-6730.
141. Otsuji S, Hirota H, Akagami H, Shibata N. Dietary eicosapentaenoic acid reduces the extent of ischemic myocardial injury through inhibition of neutrophil infiltration. Circulation 1989; 80(Suppl. II): 33.
142. Miura S, Imaeda H, Shiozaki H et al. Attenuation of endotoxin-induced intestinal microcirculatory damage by eicosapentanoic acid. Am J Physiol 1993; 264: G828-G834.
143. Steinberg H, Learning R, Cronin J et al. Elevated free fatty acids (FFA) levels impair endothelium dependent vasodilation. Diabetes 1996; 45 (Suppl. 2): 11A.
144. Schlierf G, Reinheimer W, Stossberg V. Diurnal patterns of plasma triglycerides and free fatty acids in normal subjects and in patients with endogenous (Type IV) hyperlipoproteinemia. Nutr Metabol 1971; 13: 80-91.
145. Fukagawa N K, Anderson J W, Hageman G et al. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. Am J Clin Nutr 1990; 52: 524-528.
146. Anderson J W, Zeigler J A, Deakins D A et al. Metabolic effects of high-carbohydrate, high-fiber diets for insulin-dependent diabetic individuals. Am J Clin Nutr 1991; 54: 936-943.
147. McCarty M F. Reduction of free fatty acids may ameliorate risk factors associated with abdominal obesity. Med Hypotheses 1995; 44: 278-286.
148. Som S, Raha C, Chatterjee I B. Ascorbic acid: a scavenger of Superoxide radical. Acta Vitaminol Enzymol 1983; 5: 243-250.
149. Frei B, England L, Ames B N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 1989; 86: 6377-6381.
150. Tsujimoto Y, Hashizume H, Yamazaki M. Superoxide radical scavenging activity of phenolic compounds. Int J Biochem 1993; 25: 491-494.
151. Zhao B, Li X, He R et al. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophysics 1989; 14: 175-185.
152. Heitzer T, Just H, Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996; 94: 6-9.
153. Crary E J, McCarty M F. Potential clinical applications for high-dose nutritional antioxidants. Med Hypotheses 1984; 13: 77-98.
154. Bravenboer B, Rappelle A C, Hamers F P T et al. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia 1992; 35: 813-817.
155. Cameron N E, Cotter M A, Maxfield E K. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993; 36: 299-304.
156. Anderson R, Cheng N, Bryden N et al. Beneficial effects of chromium for people with type II diabetes. Diabetes 1996; 45(Suppl. 2): 124A.
157. Jeejeebhoy K N, Chu R C, Marliss E B et al. Chromium deficiency, glucose intolerance and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition. Am J Cin Nutr 1977; 30: 531-538.
158. Freund H, Atamian S, Fischer J E. Chromium deficiency during total parenteral nutrition. J Am Med Assoc 1979; 241: 496-498.
159. Verhage A H, Cheong W K, Jeejeebhoy K N. Neurologic symptoms due to possible chromium deficiency in long-term parenteral nutrition that closely mimic metronidazole-induced syndromes. J Paren Ent Nutr 1996; 20: 123-127.
160. Nolan J J, Ludvik B, Beerdsen P et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
161. Cameron N E, Cotter M A. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia 1992; 35: 1011-1019.
162. Chen P Y, Sanders P W. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991; 88: 1559-1567.
163. Laurant P, Demolombe B, Berthelot A. Dietary L-arginine attenutates blood pressure in mineralocorticoid-salt hypertensive rats. Clin Exp Hyperten 1995; 17: 1009-1024.
164. Drexler H, Zeiher A M, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-1550.
165. Creager M A, Gallagher S J, Girerd X J et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248-1253.
166. Clarkson P, Adams M R, Powe A J et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989-1994.
167. Haddy F J. Potassium and blood vessels. Life Sci 1975; 16: 1489-1498.
168. Sugimoto T, Tobian L, Ganguli M C. High potassium diets protect against dysfunction of endothelial cells in stroke-prone spontaneously hypertensive rats. Hypertension 1988; 11: 579-585.
169. Rau L, Lüscher T F, Vanhoutte P M. High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension 1988; 12: 562-567.
170. Sudhir K, Kurtz T W, Yock P G et al. Potassium preserves endothelial function and enhances aortic compliance in Dahl rats. Hypertension 1993; 22: 315-322.
171. Tobian L. High potassium diets markedly protect against stroke deaths and kidney disease in hypertensive rats, a possible legacy from prehistoric times. Can J Physiol Pharmacol 1986; 64: 840-848.
172. Khaw K-T, Barrett-Connor E. Dietary potassium and stroke-associated mortality. N Engl J Med 1987; 316: 235-240.
173. Taddei S, Mattei P, Virdis A et al. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension 1994; 23: 485-490.
174. Hamlyn J M, Blaustein M P, Bova S et al. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991; 88: 6259-6263.
175. Blaustein M P, Hamlyn J M. Pathogenesis of essential hypertension: a link between dietary salt and high blood pressure. Hypertension 1991; 18 (Suppl. III): 184-195.
176. Woolf son R G, Poston L. Effect of ouabain on endothelium-dependent relaxation of human resistance arteries. Hypertension 1991; 17: 619-625.
177. Woolfson R G, Benjamin N, Todd S D et al. Ouabain and responses to endothelium-dependent vasodilators in the human forearm. Br J Clin Pharm 1991; 32: 758-760.
178. Weiner C P, Lizasoain I, Baylis S A et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci 1994; 91: 5212-5216.
179. Kharitonov S A, Logan-Sinclair R B, Busset C M, Shinebourne E A. Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle. Br Heart J 1994; 72: 243-245.
180. Gisclard V, Miller V M, Vanhoutte P M. Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J Pharm Exp Ther 1988; 244: 19-22.
181. Williams J K, Adams M R, Klopfenstein H S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990; 81: 1680-1687.
182. Hayashi T, Fukuto J M, Ignarro L J, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992; 89: 11259-11263.
183. Stampfer M J, Colditz G A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
184. Lobo R A. Estrogen and cardiovascular disease. Ann NY Acad Scei 1990; 592: 286-294.
185. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension 1990; 16: 532-540.
186. Becker R H A, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharm 1991; 18(Suppl. 2): S110-S115.
187. Mombouli J-V, Nephtali M, Vanhoutte P M. Effects of the converting enzyme inhibitor cilazaprilat on endothelium-dependent responses. Hypertension 1991; 18(Suppl. II): II22-II29.
188. Wiemer G, Schölkens B A, Becker R H A, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558-563.
189. Busse R, Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn-Schmiedebergs Arch Pharmacol 1991; 334: 126-129.
190. Erdös E G. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990; 15(Suppl. 6): S20-S24.
191. Kugiyama K, Kerns S A, Morrisett J D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-162.
192. Sugiyama S, Kugiyama K, Ohgushi M et al. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries: role of protein kinase C. Circ Res 1994; 74: 565-575.
193. Kugiyama K, Ohgushi M, Sugiyama S et al. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res 1992; 71: 1422-1428.
194. Braquet P. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from ginkgo biloba L. Adv Prost Thromb Leuk Res 1986; 16: 179-198.
195. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992; 340: 1136-1139.
196. Braquet P, Paubert-Braquet M, Koltai M et al. Is there a case for PAF antagonists in the treatment of ischemic states? Trends Pharm Sci 1989; 10: 23-30.
197. Ward A, Clissold S P. Pentoxyfylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97.
198. Haines E. Is pentoxifylline the drug of the decade? J Am Acad Dermatol 1994; 30: 639-642.
199. Luke D R, McCreedy B J, Sarnoski T P et al. Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients. Int J Clin Pharm Ther Toxicol 1993; 31: 343-350.
200. Dezube B J, Fridovich-Keil J L, Bouvard I et al. Pentoxifylline and wellbeing in patients with cancer. Lancet 1990; i: 662.
201. Hammerschmidt D E, Kotasek K, McCarthy T et al. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med 1988; 112: 254-263.
202. Doherty G M, Jensen J C, Alexander H R et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991; 110: 192-198.
203. van Leenen D, van der Poll T, Levi M et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993; 151: 2318-2325.
204. Dezube B J, Sherman M L, Fridovich-Keil J L et al. Downregulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993; 36: 57-60.
205. Jarrett P E M, Moreland M, Browse N L. The effect of oxpentifylline ('Trental') on fibrinolytic activity and plasma fibrinogen levels. Curr Med Res Opin 1977; 4: 492-495.
206. Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukocyte Biol 1986; 40: 747-754.
207. Strieter R M, Remick D G, Ward P A et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Comm 1988; 155: 1230-1236.
208. Cohen K L, Harris S. Pentoxifylline and diabetic neuropathy. Ann Intern Med 1987; 107: 600-601.
209. Kalmansohn R B, Kalmansohn R W, Markham C H, Schiff D L. Treatment of diabetic neuropathy with pentoxifylline: case report. Angiology 1988; 39: 371-373.
210. Rendell M, Bamisedun O. Skin blood flow and current perception in pentoxifylline-treated diabetic neuropathy. Angiology 1992; 43: 843-851.
211. Ferrari E, Fioravanti M, Patti A L et al. Effects of long-term treatment (4 years) with pentoxifylline on hemorheological changes and vascular complications in diabetic patients. Pharmatherapeutica 1987; 5: 26-39.
212. Cohen K L, Lucibello F E, Chomiak M. Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care 1990; 13: 1074-1077.
213. Kunkel S L, Ogawa H, Ward P A, Zurier R B. Suppression of chronic inflammation by evening primrose oil. Prog Lipid Res 1981; 30: 885-888.
214. Tate G, Mandell B F, Laposata M et al. Suppression of acute and chronic inflammation by dietary gamma linolenic acid. J Rheumatol 1989; 16: 729-733.
215. Tate G A, Zurier R B. Suppression of monosodium urate crystal-induced inflammation by black currant seed oil. Agents Actions 1994; 43: 35-38.
216. Leventhal L J, Boyce E G, Zurier R B. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med 1993; 119: 867-873.
217. 4. Am J Clin Nutr 1992; 55: 39-45.
218. Vanderhoek J Y, Bryant R W, Bailey J M. Regulation of leukocyte and platelet lipoxygenases by hydroxyeicosanoids. Biochem Pharmacol 1982; 31: 3463-3467.
219. Miller C C, Tang W, Ziboh V A, Fletcher M P. Dietary supplementation with ethyl ester concentrates of fish oil (n-3) and borage oil (n-6) polyunsaturated fatty acids induces epidermal generation of local putative anti-inflammatory metabolites. J Invest Dermatol 1991; 96: 98-103.
220. 4 release from activated neutrophils. Proc Natl Acad Sci USA 1983; 80: 4349-4353.
221. Kuehl F A Jr, Dougherty H W, Ham E A. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984; 33: 1-5.
222. Simpson P J, Mitsos S E, Ventura A et al. Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 1987; 113: 129-137.
223. Simpson P J, Mickelson J, Fantone J C et al. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res 1987; 60: 666-673.
224. Jamal G A, Carmichael H, Weir A I. Gamma-linolenic acid in diabetic neuropathy. Lancet 1986; i: 1098.
225. The γ-Linolenic Acid Multicenter Trial Group. Treatment of diabetic neuropathy with γ-linolenic acid. Diabetes Care 1993; 16: 8-15.
226. Jamal G A. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabetic Med 1994; 11: 145-149.
227. Pfeifer M A, Schumer M P. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 1995; 44: 1355-1361.
228. + pump in streptozotocin-diabetic rats. Br J Pharmacol 1992; 105: 355-360.
229. Dines K C, Cotter M A, Cameron N E. Contrasting effects of treatment with ω-3 and ω-6 essential fatty acids on peripheral nerve function and capillarization in streptozotocin-diabetic rats. Diabetologia 1993; 36: 1132-1138.
230. Houtsmiller A J, van Hal-Ferwerda J, Zahn K J, Henkes H E. Favorable influences of linoleic acid on the progression of diabetic micro- and macroangiopathy in adult onset diabetes mellitus. Prog Lipid Res 1981; 20: 377-386.
231. Bunting S R, Gryglewski R, Moncada A S, Vane J R. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897-913.
232. Kyle V, Hazleman B. Prostaglandin E1 and peripheral vascular disease. Lancet 1983; ii: 282.
233. 2+-dependent protein kinases. Biochem J 1989; 258: 57-65.
234. Kunisaki M, Umeda F, Inoguchi T, Nawata H. Vitamin E restores reduced prostacyclin synthesis in aortic endothelial cells cultured with a high concentration of glucose. Metabolism 1992; 41: 613-621.
235. 2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 1990; 15: 475-481.
236. 2 as an endothelium-derived contracting factor in diabetic state. Diabetes 1993; 42: 1246-1252.
237. Sicuteri F, Franchi G, Fanciullacci M et al. Sull'azione antianginosa di un aminoacido solforato non coronariodilatotore. Clin Ter 1969; 49: 205-219.
238. Becattini U. Prospettive di un nuovo farmaco nelia terapia delle vasculopatie: la taurina. Sett Med 1967; 55: 1355-1361.
239. Montanini R, Gasco P. La taurina nel trattamento delle arteriopatie cerebrali diffuse. Clin Ter 1974; 71: 427-436.
240. Montanini R, Zibetti A, Gasco P. Osservazioni preliminari sull'impiego della taurina nel trattamento delle vasculopatie cerebrali. Clin Ter 1971; 59: 321-329.
241. Milei J, Ferreira R, Llesuy S et al. Reduction of reperfusion injury with preoperative rapid intravenous infusion of taurine during myocardial revascularization. Am Heart J 1992; 123: 339-345.
242. Raschke P, Massoudy P, Becker B F. Taurine protects the heart from neutrophil-induced reperfusion injury. Free Rad Biol Med 1995; 19: 461-471.
243. McCarty M F. Complementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate. Med Hypotheses 1996; 46: 89-100.
244. McNair P, Christiansen C, Madsbad S et al. Hypomagnesemia, a risk factor in diabetic retinopathy. Diabetes 1978; 27: 1075-1077.
245. Mather H M, Levin G E, Nisbet J A. Hypomagnesemia and symptomatic ischemic heart disease in diabetes. Magnesium Bull 1981; 3: 169-172.
246. Sjögren A, Florén C-H, Nilsson Å. Magnesium deficiency in IDDM related to level of glycosylated hemoglobin. Diabetes 1986; 35: 459-463.
247. Paolisso G, Sgambata S, Pizza G et al. Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care 1989; 12: 265-269.
248. Sjögren A, Florén C-H, Nilsson Å. Oral administration of magnesium hydroxide to subjects with insulin-dependent diabetes mellitus: effects on magnesium and potassium levels and on insulin requirements. Magnesium 1988; 7: 117-122.
249. Chen C C, Rosenbloom C L, Anderson D C, Manning A M. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of IκB-α phosphorylation. J Immunol 1995; 155: 3538-3545.
250. Collins T. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion. Lab Invest 1993; 68: 499-508.
251. Sen C K, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996; 10: 709-720.
252. Suzuki Y J, Aggarwal B B, Packer L. α-Lipoic acid is a potent inhibitor of NF-κB activation in human T cells. Biochem Biophys Res Comm 1992; 189: 1709-1715.
253. Packer L, Witt E H, Tritschler H J. Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med 1995; 19: 227-250.
254. Endres S, Ghorbani R, Kelley V E et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-271.
255. Renier G, Skamene E, DeSanctis J, Radzioch D. Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Arterioscler Thromb 1993; 13: 1515-1524.
256. Yoshizumi M, Perrella M A, Burnett J C Jr, Lee M-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.
257. Cherchi A, Lai C, Angelino F et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicentre, double-blind, randomized placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985; 23: 569-572.
258. Brevetti G, Chiariello M, Ferulano G et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77: 767-773.
259. Cerretelli P, Marconi C. L-Carnitine supplementation in humans. The effects on physical performance. Int J Sports Med 1990; 11: 1-14.
260. Lowitt S, Malone J, Salem A, Korthals J. Acetylcarnitine improves neuronal function in streptozotocin (STZ) diabetic rats. Diabetes 1990; 39: 155A.
261. Solerte S B, Fioravanti M, Bozzetti A et al. Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria: results of a short-term randomized study. Acta Diabetol Lat 1986; 23: 171-177.
262. Tripathy I, Prakash J, Appaiha D, Srivastava P K. Pentoxifylline in management of proteinuria in diabetic nephropathy. Nephron 1993; 64: 641-642.
263. Paolisso G, D'Amore A, Giugliano D et al. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr 1993; 57: 650-656.
264. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin dependent diabetes mellitus. Ann Intern Med 1988; 108: 663-668.
265. Friday K E, Childs M T, Tsunehara C H et al. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes Care 1989; 12: 276-281.
266. Harris W S. Do ω3 fatty acids worsen glycemic control in NIDDM? ISSFAL Newslett 1996; 3: 6-9.
267. Spellacy W N. Menopause, estrogen treatment, and carbohydrate metabolism. In: Mishell D R Jr, ed. Menopause: Physiology and Pharmacology. Chicago: Year Book Medical Publishers, 1987: 253-260.